Keyword: Calquence

To show Brukinsa is better than AbbVie and J&J's blockbuster Imbruvica, BeiGene is running phase 3 head-to-head trials in blood cancers.

AbbVie is riding high on the launch of RA blockbuster-to-be Rinvoq and a looming merger with Allergan. Could competition for Imbruvica be a buzzkill?

AstraZeneca’s cancer meds put on another good show, with PD-L1 drug Imfinzi and Merck & Co.-shared Lynparza both headed for the blockbuster line.

AstraZeneca is rolling with a series of trial wins for Calquence in CLL. Will those data help the drug challenge Imbruvica’s blockbuster sales?

AstraZeneca’s Calquence has been battling it out in MCL, but the company has had its eye on CLL. And that’s where it’s scored its latest win.

When it comes to CLL, AZ is looking to push Imbruvica aside with newcomer Calquence. But based on some new data, one analyst doesn’t see it happening.

AstraZeneca and pro golfer Jason Day have teamed up on a campaign to encourage biomarker testing for lung cancer patients.

Chasing big fish in the BTK inhibitor market, AstraZeneca’s Calquence was looking for a leg up. New clinical data show promise in leukemia.

For the second straight year, AstraZeneca is spending the fall launching a hemo-oncology drug.

Just a year after approval, AZ’s Calquence is giving Imbruvica a run for its money in MCL. But the British drugmaker doesn’t want to stop there.